Biocept to Present at the LD Micro Virtual Invitational XI Conference on June 9, 2021
“We look forward to providing investors with an update on CNSide™, our novel assay that provides physicians with a significantly improved tool to diagnose and manage patients with tumors that have metastasized to the central nervous system,” said
Investors and other interested parties can register before Biocept’s presentation here. Following the presentation, the webcast will be available on the Company’s website for 90 days.
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20210603005099/en/
Investor Contact:
Jcain@lhai.com, 310-691-7100
Media Contact:
asampson@sampsonprgroup.com, (562) 304-0301
Source: